Intranasal Drug Delivery

Intranasal Drug Delivery

Global Intranasal Drug Delivery Market to Reach US$92.6 Billion by 2030

The global market for Intranasal Drug Delivery estimated at US$59.1 Billion in the year 2023, is expected to reach US$92.6 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2023-2030. Liquid Delivery Devices, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$38.0 Billion by the end of the analysis period. Growth in the Powder Delivery Devices segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.6 Billion While China is Forecast to Grow at 8.9% CAGR

The Intranasal Drug Delivery market in the U.S. is estimated at US$24.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.1 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Global Intranasal Drug Delivery Market - Key Trends and Drivers Summarized

Intranasal drug delivery refers to the administration of medications through the nasal cavity, offering a non-invasive and efficient route for drug absorption. This method leverages the rich vascularization and large surface area of the nasal mucosa, enabling rapid onset of action and enhanced bioavailability compared to other non-invasive routes. Intranasal delivery systems are utilized for a variety of drugs, including those for pain management, neurological disorders, and vaccinations. The technology behind these systems includes metered-dose nasal sprays, nasal gels, and powder formulations, each designed to optimize drug absorption and minimize systemic side effects.

The application of intranasal drug delivery spans several therapeutic areas, making it a versatile tool in modern medicine. It is particularly beneficial in emergency situations where rapid drug action is critical, such as with naloxone for opioid overdoses or epinephrine for anaphylactic reactions. Additionally, intranasal delivery is increasingly used for chronic conditions like migraines and hormonal therapies, where it offers a convenient and non-invasive alternative to injections. The ability to bypass the gastrointestinal tract and first-pass metabolism in the liver also makes this route advantageous for drugs that are poorly absorbed orally or extensively metabolized.

The growth in the intranasal drug delivery market is driven by several factors, including advancements in delivery technologies, increasing prevalence of chronic and acute conditions requiring rapid intervention, and a growing preference for non-invasive administration methods among patients and healthcare providers. Technological innovations, such as improved formulations and novel delivery devices, enhance drug stability and absorption, expanding the range of treatable conditions. Additionally, demographic trends such as aging populations and rising incidences of conditions like Alzheimer`s disease and Parkinson`s disease fuel demand for more effective drug delivery systems. Consumer behavior shifts towards self-administration and home care, coupled with healthcare cost containment strategies, further propel market expansion. The development of intranasal vaccines, particularly highlighted by the COVID-19 pandemic, also underscores the critical role of this delivery method in global health strategies.

Select Competitors (Total 77 Featured) -

• Acorda Therapeutics, Inc.
• Ferring Pharmaceuticals Inc
• Bespak Europe Ltd.
• Breckenridge Pharmaceutical, Inc.
• Janssen Global Services LLC
• Hikma Pharmaceuticals PLC
• Biologische Heilmittel Heel GmbH
• Evoke Pharma, Inc.
• KemPharm, Inc.
• Impel NeuroPharma
• Actiza Pharmaceutical Pvt., Ltd.
• Covis Pharma
• H&T Presspart Manufacturing Ltd.
• Biomedica International
• Alchemy Pharmatech Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.